COMBINATION CARDIOMETABOLIC THERAPY IN TYPE 2 DIABETES: OPTIMIZING SGLT2 INHIBITOR AND GLP‑1 RECEPTOR AGONIST USE

Descargar Publicación
Oral nonpeptide GLP-1 receptor agonist VCT220 for obesity treatment: a randomized, double-blind, phase II trial The Gut–brain–adipose Axis in Ultra-processed Food and Obesity: A Mechanistic Synthesis and Its Implications for Food Classification